Results 181 to 190 of about 953,056 (326)

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Correction: Molecular resistance mechanisms to newly approved antibiotics (2017-2025) in WHO priority pathogens. [PDF]

Front Microbiol
Frontiers Production Office.
europepmc   +1 more source

Risk factors for Enasidenib in the treatment of Acute Myelogenous Leukemia and subgroups analysis: pharmacovigilance of the FDA adverse event reporting system (FAERS) [PDF]

XIE JIANGCHUAN, Qian Gao, Yu Qin, Li Xie, Yongchuan Chen   +4 more
openalex   +1 more source

A Physiological Microfluidic Blood–Brain‐Barrier Model for In Vitro Study of Nanoparticle Trafficking and Accumulation

Advanced Healthcare Materials, EarlyView.
A human microfluidic blood‐brain barrier (mBBB) model enables spatially resolved comparison of nanoparticle trafficking. Extracellular vesicles (EVs), liposomes, and nanoplastics exhibit distinct transport and disruption behaviors, revealing that membrane composition and uptake pathways govern BBB interaction.
Bryan B. Nguyen, Neona M. Lowe, Sophia Kellogg, Kuan‐Wei Huang, Hannah O'Toole, Elizabeth J. Hale, Venktesh S. Shirure, Bhupinder S. Shergill, Steven C. George, Randy P. Carney   +9 more
wiley   +1 more source

Supplementary Table S2 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy [PDF]

Robert Q. Le, Kamar Godder, Jingyan Wang, Justin S. Collazo, Robyn Konicki, Moran Choe, Monica Feng, Donna Przepiorka, Jonathon Vallejo, Ankit Shah, Jiang Liu, Brenda J. Gehrke, Willie Wilson, Andrea Siegel, Yun Wu, Charles Yuan-Chia Kuo, Melissa Ray, Richard Pazdur, Marc R. Theoret, R. Angelo de Claro   +19 more
openalex   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

Advanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa, Gracia Mendoza, Silvia Irusta, Manuel Arruebo   +3 more
wiley   +1 more source

Author Correction: Regulatory review of benefits and risks of preventing infant RSV disease through maternal immunization

npj Vaccines
Yugenia K. Hong-Nguyen, Joseph Toerner, Lucia Lee, Maria C. Allende, David C. Kaslow   +4 more
doaj   +1 more source

Innovation breakthrough in the Alzheimer's disease pharmaceutical industry. [PDF]

NPJ Drug Discov
Cheng H, Kang L, Xu Y, Tanzi RE, Zhang C, Wang C.   +5 more
europepmc   +1 more source

Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects

Advanced Materials, EarlyView.
Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley   +1 more source

Regulatory, ethical, and clinical barriers to exosome use in interventional pain medicine. [PDF]

Interv Pain Med
Bourcier AJ, Kirkor ZM.
europepmc   +1 more source